Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial

Y J He1,2,3,4, S J Winham5,6, J M Hoskins3

  • 1Department of Clinical Pharmacology, Xiang-Ya Hospital, Central South University, Changsha, China.

The Pharmacogenomics Journal
|July 22, 2015
PubMed

Insights

Genetic variants in ATP7B, GSR, VEGFA, and SCN10A genes are linked to severe gastrointestinal (GI) toxicity in ovarian cancer patients receiving carboplatin/taxane chemotherapy. These findings may help predict and manage treatment side effects.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Genetics

Background:

  • Carboplatin/taxane chemotherapy is a standard first-line treatment for ovarian cancer.
  • Chemotherapy-induced gastrointestinal (GI) toxicity can lead to treatment delays, reduced quality of life, and increased mortality.

Purpose of the Study:

  • To investigate the association between genetic variants and severe (grade III/IV) chemotherapy-induced GI toxicity in ovarian cancer patients.
  • To identify potential genetic markers for predicting and managing GI toxicity.

Main Methods:

  • A candidate gene study was performed on 808 ovarian cancer patients from the SCOTROC1 trial.
  • Patients were divided into discovery (404 patients) and validation (404 patients) cohorts.
  • Genetic variants and clinical covariates associated with GI toxicity were analyzed.

Main Results:

  • Seven single-nucleotide polymorphisms (SNPs) in ATP7B, GSR, VEGFA, and SCN10A genes were significantly associated with grade III/IV GI toxicity.
  • Patients with risk genotypes had 1.53 to 18.01 times higher odds of developing severe GI toxicity (P<0.01).
  • VEGF gene variants showed a marginal association with patient survival time.

Conclusions:

  • Specific genetic variants in ATP7B, GSR, VEGFA, and SCN10A may predict carboplatin/taxane-induced GI toxicity in ovarian cancer.
  • These findings offer potential targets for therapeutic strategies to mitigate GI toxicity.
  • Further research could lead to personalized medicine approaches for ovarian cancer treatment.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
69
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
184
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K